This trial is testing a new drug to treat myasthenia gravis, a rare autoimmune disease that causes muscle weakness. The drug is given either once a week or every two weeks, and the trial will measure how effective it is in treating the disease.
1 Primary · 9 Secondary · Reporting Duration: Baseline (Week 12) to Week 24
210 Total Participants · 6 Treatment Groups
Primary Treatment: Batoclimab 680 mg SC weekly · Has Placebo Group · Phase 3
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: